We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+17.75%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$115M
Cap. Flow
+$86.6M
Cap. Flow %
21.93%
Top 10 Hldgs %
76.35%
Holding
48
New
11
Increased
6
Reduced
8
Closed
13

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$79M
2
VRNA
Verona Pharma
VRNA
+$16.9M
3
BSX icon
Boston Scientific
BSX
+$13.1M
4
INSM icon
Insmed
INSM
+$11.5M
5
DGX icon
Quest Diagnostics
DGX
+$9.32M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$17.2M
2
PCVX icon
Vaxcyte
PCVX
+$13.3M
3
NUVL
Nuvalent
NUVL
+$8.86M
4
RVMD icon
Revolution Medicines
RVMD
+$7.31M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 86.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.01B
$1.72M 0.43%
316,700
+100,000
+46% +$700K
NBIX icon
27
Neurocrine Biosciences
NBIX
$16.7B
$1.63M 0.41%
14,700
-30,300
-67% -$3.84M
UTHR icon
28
United Therapeutics
UTHR
$22.3B
$1.54M 0.39%
+5,000
New +$1.71M
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.2B
$1.34M 0.34%
40,000
– –
ASND icon
30
Ascendis Pharma A/S
ASND
$16B
$1.16M 0.29%
7,440
– –
JANX icon
31
Janux Therapeutics
JANX
$971M
$1.03M 0.26%
38,100
-124,876
-77% -$4.71M
MREO
32
Mereo BioPharma
MREO
$50.8M
$948K 0.24%
421,359
– –
TVTX icon
33
Travere Therapeutics
TVTX
$5.91B
$554K 0.14%
+30,900
New +$627K
CNTA
34
DELISTED
Centessa Pharmaceuticals
CNTA
$507K 0.13%
35,226
-45,154
-56% -$739K
ORKA
35
Oruka Therapeutics
ORKA
$5.79B
$75.7K 0.02%
+7,380
New +$92K
ANNX icon
36
Annexon
ANNX
$875M
– –
-172,226
Closed -$884K
CRL icon
37
Charles River Laboratories
CRL
$12.6B
– –
-6,305
Closed -$1.16M
CRNX icon
38
Crinetics Pharmaceuticals
CRNX
$8.9B
– –
-45,765
Closed -$2.34M
ELVN icon
39
Enliven Therapeutics
ELVN
$4.13B
– –
-102,900
Closed -$2.32M
EWTX icon
40
PUT
Edgewise Therapeutics
EWTX
$4.79B
– –
-50,000
Closed -$1.33M
NAMS icon
41
NewAmsterdam Pharma
NAMS
$3.1B
– –
-54,285
Closed -$1.4M
NVO
42
CALL
Novo Nordisk
NVO
$199B
– –
-50,000
Closed -$4.3M
NVO
43
Novo Nordisk
NVO
$199B
– –
-200,000
Closed -$17.2M
NVO
44
PUT
Novo Nordisk
NVO
$199B
– –
-200,000
Closed -$17.2M
PCVX icon
45
Vaxcyte
PCVX
$7.99B
– –
-162,255
Closed -$13.3M
TARS icon
46
Tarsus Pharmaceuticals
TARS
$2.63B
– –
-20,811
Closed -$1.15M
XBI icon
47
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-100,000
Closed -$9.01M
TECX
48
Tectonic Therapeutic
TECX
$557M
– –
-16,650
Closed -$769K
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Artia Global Partners held 48 positions worth $395M, up 41% from $280M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artia Global Partners deployed $86.6M of net new capital in Q1 2025, opening 11 new positions and adding to 6 existing holdings. Its largest new stake was Eli Lilly: 94,887 shares worth $78.4M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $8.86M trimmed.

  • Artia Global Partners's largest Q1 2025 buy was Eli Lilly: 94,887 shares worth $78.4M.
  • Artia Global Partners added most to Verona Pharma in Q1 2025, an estimated $16.9M increase.
  • Artia Global Partners's biggest Q1 2025 reduction was Nuvalent, cutting an estimated $8.86M.
  • Artia Global Partners fully exited Novo Nordisk in Q1 2025, selling an estimated $17.2M.
  • Artia Global Partners's ten largest holdings make up 76% of its $395M portfolio in Q1 2025.
  • Artia Global Partners opened 11 new positions and closed 13 in Q1 2025.
  • Artia Global Partners's portfolio value rose 41% quarter-over-quarter to $395M.

Based on Artia Global Partners's 13F filing for Q1 2025, filed 15 May 2025.